We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > C21

News List

Vicore Pharma’s C21 med shows promise in COVID-19 study pharmatimes
December 24, 2020
Vicore Pharma’s lead candidate drug C21 has scored some promising results in a study evaluating the medicine in hospitalised COVID-19 patients.
Positive top line data released for study of C21 in COVID-19 patients europeanpharmaceuticalreview
December 10, 2020
In hospitalised COVID-19 patients, researchers found that C21 reduced the risk of needing oxygen at the end of treatment by 40 percent.
Vicore Pharma recruits the first patient in the phase 2 proof-of-concept study in idiopathic pulmonary fibrosis pharmaceutical-business-review
November 18, 2020
Vicore Pharma Holding AB (publ), a pharmaceutical company dedicated to developing innovative medicines for rare lung disorders, announces that the first patient in the phase II idiopathic pulmonary fibrosis (IPF) study has been recruited in India.